

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G. A. Doherty, et al.

Serial No. 10/339,380

Filed: January 9, 2003

For: SELECTIVE S1P1/EDG1 RECEPTOR AGONISTS

Art Unit: 1626

Examiner: _____

Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

EXPRESS MAIL CERTIFICATE
 DATE OF DEPOSIT 7-12-04
 EXPRESS MAIL NO. 9509 1689 US
 I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
 BEING DEPOSITED WITH THE UNITED STATES POSTAL
 SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
 ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
 COMMISSIONER FOR PATENTS, P.O. BOX 1450,
 ALEXANDRIA, VIRGINIA 22313-1450.
 MAILED BY Chris Schepise
 DATE July 12, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By _____

Date _____

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SJL/

DT15 Rec'd PCT/PTO 12 JUL 2004

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

| RELATED APPLICATION | | |
|---------------------|-------------|------------|
| U. S. SERIAL NUMBER | FILING DATE | MERCK CASE |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Raynard Yuro

Attorney _____ For Applicant(s)

Reg. No. 45,570

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-0182

Date: July 12, 2004

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SJL/

*Examiner: Initial if reference considered whether or not citation is in conformity with MPEP 609. Draw line through citation and not in conformity and not considered. Include copy of this form with next communication to applicant.

* Substitute for form 1449B/PTO**COMPL. OF KNOWN****Application Number**

To be assigned

10/501176

Filing Date**First Named Inventor**

G. A. Doherty, et al.

Group Art Unit

Examiner Name

Sheet

2

of

2

Attorney Docket Number

21014YP

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

AA

Timothy Hlat, et al., "An Abundant Transcript Induced in Differentiating Human Endothelial Cells Encodes a Polypeptide with Structural Similarities to G-protein-coupled Receptors", *The Journal of Biological Chemistry*, Vol. 265, No. 18, pp. 9308-9313 (1990)

AB

Songzhu An, et al., " Identification of cDNAs Encoding Two G Protein-coupled Receptors for Lysosphingolipids", Federation of European Biochemical Societies, Vol. 417, pp. 279-282 (1997)

AC

David C. Lado, et al., "Cloning of the Rat Edg-1 Immediately-early Gene: Expression Pattern Suggests Diverse Functions", *Gene*, Vol. 49, pp. 331-336 (1994)

AD

Herbert M. Himmel, et al., "Evidence for Edg-3 Receptor-Mediated Activation of /K.ACh by Sphingosine-1-Phosphate in Human Atrial Cardiomyocytes", *Molecular Pharmacology*, Vol. 58, pp. 449-454 (2000)

AE

Nobuko Nakajima, et al., "Expression and Characterization of Edg-1 Receptors in Rat Cardiomyocytes Calcium Deregulation in Response to Sphingosine 1-Phosphate", Eur. J. Biochem., Vol. 267, pp. 5679-5686 (2000)

AF

Atsushi Sugiyama, et al., "Effects of Sphingosine 1-Phosphate, a Naturally Occurring Biologically Active Lysophospholipid, on the Rat Cardiovascular System", Jp. J. Pharmacol., Vol. 82, pp. 338-342 (2000)

AG

B. D. Kahan, "FTY720: A New Dimension in Transplantation" Elsevier Science, Inc., Transplantation Proceedings, Vol. 33, pp. 3081-3083 (2001)

Examiner
Signature

/Samira Jean-Louis/

Date Considered

11/14/2007

*Examiner: Initial if reference considered, where the origin of citation is in conformance with NRCB 609. Draw line through citation if not in conformance, and not considered. The back copy of this form with next communication to be attached.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003